Role of Activated Protein C Resistance in Left Atrial Thrombogenesis in Patients with Mitral Stenosis

Abstract

Activated protein C resistance (APC-R) is the most common inherited cause of clinically apparent venous thromboembolism. Previous data indicate that left atrial thrombus (LAT) formation is a common complication in mitral stenosis (MS) and a hypercoagulable state exists in these patients. The aim of this study was to invastigate the association between APC-R and LAT formation in patients with MS. Seventy-seven consecutive patients with rheumatic MS were included in this study. Transesophageal echocardiography was performed on all patients to assess the presence of any thrombus or spontaneous echo contrast (LASEC) in the left atrial cavity or appendage. Thirty four of the patients had LAT and 43 did not. Prevelance of APC-R was smiliar between the two groups of patients with and without LAT (23% vs 16%, p=0.425). LAT(+) patients had higher incidence of atrial fibrillation (AF, 74% vs 51%, p=0.046) and LASEC (71% vs 19%, p<0.001) compared to LAT(-) patients. On multivariate regression analysis, only the presence of LASEC achieved statistical significance as an independent risk factor for LAT formation (p=0.0001, odds ratio=9.589, 95% confidence interval [CI] =3.143-29.251). Because on (continued on next page) univariate analysis both LASEC and AF were associated with LAT, we also compared the prevelance of APC-R in the subgroups of patients who have these risk factors with and without LAT. There was a correlation between the presence of APC-R and LAT in the AF(+) subgroup of MS patients (p=0.033, odds ratio=8.167, 95% CI=1.001-72.812). However, the presence of APC-R was not associated with the increased risk of LAT in LASEC(+) patients (p=0.217, odds ratio =1.200, 95% CI=1.003-1.435). Although the presence of APC-R itself is not an independent risk factor for LAT formation in MS, it may increase the risk of LAT when present in combination with AF (as an additional risk factor) in these patients.

Get full access to this article

View all access options for this article.

References

Bertina R. , Koeleman B. , Koster T. , et al: Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369:64-67, 1994.

Dahlback B. : Inherited thrombophilia: resistance to activated protein C as a pathogenic risk factor of venous thromboembolism. Blood 85:607-614, 1995.

Svenson P. , Dahlback B. : Resistance to activated protein C as a basis for venous thrombosis . New Engl J Med 330:517-522, 1994.

Koster T. , Rosendaal FR , de Ronde H. , et al: Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 342:1503-1506, 1993.

Rosendaal FR , Koster T. , Vandenbroucke JP , et al: High risk of thrombosis in patients homozygous for factor V leiden (activated protein C resistance). Blood 85:1504-1508, 1995 .

Rittoo D. , Sutherland GR , Currie P. , et al: A prospective study of left atrial spontaneous echo contrast and thrombus in 100 consecutive patients referred for balloon dilatation of the mitral valve. J Am Soc Echocardiogr 7:516-527, 1994.

Vigna C. , de Rito V. , Cricino GM , et al: Left atrial thrombus and spontaneous echo-contrast in nonanticoagulated mitral stenosis: A transesophageal echocardiographic study. Chest 103:348-352, 1993.

Chiang CW , Lo SK , Kuo CT , et al: Noninvasive predictors of systemic embolism in mitral stenosis: An echocardiographic and clinical study of 500 patients. Chest 106:396-399, 1994.

Danial WG , Nellessen U. , Schroder E. , et al: Left atrial spontaneous echo-contrast in mitral valve disease: An indicator of increased thromboembolic risk. J Am Coll Cardiol 11:1204-1211, 1988.

10.

Dahlback B. , Carlsson M. , Svensson PJ : Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C Proc Natl Acad Sci USA 90:1004, 1993.

11.

Halbmayer WM , Haushofer A. , Schön R. , et al: The prevelance of poor anticoagulan response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects . Blood Coagul Fibrinol 5:51, 1994.

12.

Holm J. , Zöller B. , Svensson PJ , et al: Myocardial infarction in two young women associated with homozygous resistance to activated protein C. Lancet 344:952, 1994.

13.

Lindblad B. , Svensson PJ , Dahlback B. : Arterial and venous thromboembolism with fatal outcome in a young man with inherited resistance to activated protein C Lancet 343:917, 1994.

14.

Press RD , Liu XY , Beamer N. , et al: Ischemic stroke in the elderly. Role of common factor 5 mutation cousing resistance to activated protein C. Stroke 27: 44-48, 1996.

15.

Emmerich J. , Poirier O. , Evans A. , et al: Myocardial infarction, Arg 506 to Gln factor 5 mutation and activated protein C resistance (Letter) . Lancet 345:321, 1995.

16.

Dahlback B. : Resistance to activated protein C as Risk factor for thrombosis: Molecular mechanisms, laboratory investigation and clinical management. Semin Hematol 34:217-234, 1997.

17.

Peverill RE , Herper RW , Gelman J. , et al: Determinants of increased regional left atrial coagulation activity in patients with mitral stenosis. Circulation 94:331-339, 1996.

18.

Ileri M. , Büyükaşsik Y. , Ileri NS : Activation of blood coagulation in patients with mitral stenosis and sinus rhythm. Am J Cardiol 81:795-797, 1998.

19.

Vandenbroucke JP , Koster T. , Briet E. : Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V leiden mutation. Lancet 344: 1453-1457, 1994 .

20.

Bokarewa MI , Bremme K. , Blomback M. , et al: Arg506-Gln mutation in factor V and risk of thrombosis during pregnancy. Br J Haematol 92:473-478, 1996.

21.

Mandel H. , Brenner B. , Berant M. , et al: Coexistence of hereditary homocystinuria and factor V leiden- effect on thrombosis. N Engl J Med 334:763-768, 1996.